Cancer Diagnostics Market Size, Share, Growth, and Industry Analysis, By Type (Laboratory Tests,Genetic Tests,Imaging,Endoscopy,Biopsy), By Application (Breast Cancer,Lung Cancer,Colorectal Cancer,Melanoma,Others), Regional Insights and Forecast to 2035

Cancer Diagnostics Market Overview

Global Cancer Diagnostics Market valued at USD 26913.05 Million in 2026, projected to reach USD 114002.16 Million by 2035, growing at a CAGR of 17.4%.

The global Cancer Diagnostics Market is experiencing robust expansion due to increasing cancer incidence and advances in diagnostic technologies. As of 2025, over 19.8 million new cancer cases are diagnosed globally each year, driving demand for early detection tools. Imaging techniques such as MRI and CT scans are used in 67% of all cancer diagnostic procedures. Laboratory tests contribute to 48% of routine cancer screening globally, particularly in breast and prostate cancer diagnostics. Biopsy procedures are used in 59% of confirmed cancer diagnoses, making them a central pillar in clinical assessment.

The United States dominates the Cancer Diagnostics Market with over 22.3% of global market share. In 2025, more than 1.9 million new cancer cases are expected to be diagnosed across the country. Mammography remains the most used diagnostic tool, deployed in 74% of breast cancer screenings. Liquid biopsy usage has increased by 46% in the past three years due to its non-invasive advantages. The FDA has approved over 160 cancer diagnostic products in the United States since 2023.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: Over 61% increase in early cancer screening demand has directly accelerated diagnostic service adoption across hospitals and specialty clinics.
• Major Market Restraint: Approximately 49% of patients in developing regions report affordability issues and limited access to advanced diagnostic infrastructure.
• Emerging Trends: Integration of AI tools in diagnostics has expanded by 53% globally, enhancing accuracy and reducing turnaround time for cancer detection.
• Regional Leadership: North America holds 33% of global Cancer Diagnostics Market Share due to strong healthcare infrastructure and high insurance penetration.
• Competitive Landscape: Two major players hold a combined 36% of global diagnostic equipment and solutions used in cancer screening and analysis.
• Market Segmentation: Laboratory tests account for 29%, imaging for 33%, and genetic tests for 17% of overall diagnostics procedures performed worldwide.
• Recent Development: Between 2023 and 2025, over 57 new diagnostic product launches and AI tools were introduced by leading cancer diagnostics companies.

Cancer Diagnostics Market Latest Trends

Precision diagnostics and liquid biopsies are dominating recent Cancer Diagnostics Market Trends. Liquid biopsies are now used in 31% of metastatic cancer assessments, improving detection of recurrence.

Wearable health monitors linked with diagnostic platforms have increased patient-generated data contribution by 38% in cancer assessments. Companion diagnostics in oncology drug development now support 47% of new drug approvals. Immunohistochemistry is utilized in 49% of biopsies to confirm cancer type and subtype.

Cancer Diagnostics Market Dynamics

DRIVER

"Rising demand for early and accurate detection technologies"

The surge in early-stage detection efforts is transforming the Cancer Diagnostics Market. Around 64% of oncology professionals prioritize diagnostic accuracy to determine personalized treatment protocols. Rising global cancer incidence—estimated at 19.8 million new cases annually—has compelled 58% of healthcare systems to introduce or expand national screening programs. Precision diagnostic tools are being adopted in 62% of tertiary care centers, especially for breast, lung, and colorectal cancers. Over 72 countries have made imaging tools such as PET and CT scans available under public healthcare by 2025.

RESTRAINT

"High cost of diagnostic technologies and services"

Cancer diagnostics often involve expensive equipment and processes, limiting adoption in low-income regions. Advanced imaging and genetic tests cost 48% more than traditional laboratory tests. Approximately 53% of patients in Sub-Saharan Africa and Southeast Asia face accessibility issues. Insurance coverage for molecular diagnostics is limited to only 37% of policies in emerging economies. High-end biopsy tools, including robotic-guided devices, are deployed in only 19% of facilities in underdeveloped areas, according to the Cancer Diagnostics Market Forecast.

OPPORTUNITY

"Expansion of personalized medicine and biomarker research"

The rise in biomarker-based therapies has opened new growth avenues in the Cancer Diagnostics Market. Currently, 51% of pharmaceutical clinical trials are co-developed with companion diagnostics. Biomarker-based detection methods are used in 38% of lung cancer diagnoses. Cancer-specific gene panels have become available in 42% of research hospitals globally. Personalized screening plans are offered in 57% of private cancer care centers. Genomics-based diagnostics are expected to rise further as targeted therapy use expands.

CHALLENGE

"Complex regulatory pathways and long approval timelines"

Obtaining approvals for novel diagnostic technologies remains a significant hurdle. It takes approximately 18 to 24 months for new cancer diagnostic tools to secure regulatory clearance in major markets. Only 41% of submissions meet the initial acceptance criteria in the first review cycle. Harmonizing global regulatory frameworks has been a challenge, with 46% of manufacturers reporting country-specific delays. Cross-border diagnostic trials face 29% more documentation requirements compared to therapeutic trials.

Cancer Diagnostics Market Segmentation

The Cancer Diagnostics Market is segmented by type and application, addressing both technological usage and disease-specific demand. Imaging and laboratory testing dominate usage, while applications remain highly specific to cancer type.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Laboratory Tests: Laboratory tests account for 29% of global cancer diagnostics procedures. Blood biomarker screening is used in 52% of routine checks, while tumor markers such as PSA and CA-125 contribute to 48% of detection practices. Automated hematology and immunoassay platforms are used in 63% of diagnostic laboratories globally.

The Laboratory Tests segment of the Cancer Diagnostics Market is anticipated to reach USD 24,431.18 million by 2034, securing 25.16% market share and expanding at a CAGR of 16.9% during the forecast period.

Top 5 Major Dominant Countries in the Laboratory Tests Segment

• United States: Forecasted to reach USD 6,170.38 million with 25.24% market share and 16.8% CAGR, supported by high adoption across hospitals and diagnostic laboratories.
• Germany: Expected to achieve USD 2,411.36 million, accounting for 9.87% share with 16.5% CAGR, driven by early detection initiatives and public healthcare investments.
• Japan: Market value projected at USD 2,205.94 million with 9.03% share and 17.1% CAGR, due to technological innovation and diagnostic expansion programs.
• China: Estimated to hit USD 2,841.59 million with 11.63% market share and 17.6% CAGR owing to rapid urban healthcare infrastructure development.
• India: Forecasted to grow to USD 1,580.12 million with 6.47% share and a strong CAGR of 17.9%, encouraged by increasing private diagnostic chains.

Genetic Tests: Genetic tests represent 17% of cancer diagnostic practices. BRCA1/BRCA2 testing is conducted in 54% of breast cancer cases with family history. Next-generation sequencing (NGS) is used in 49% of genomic panels. Over 160 cancer genes are now included in screening protocols.

The Genetic Tests segment is expected to attain USD 16,047.98 million by 2034, capturing 16.52% of total market share while registering a CAGR of 18.7% from 2025 to 2034.

Top 5 Major Dominant Countries in the Genetic Tests Segment

• United States: Projected to command USD 5,942.24 million with 37.03% share and 18.3% CAGR, led by expansion in BRCA and companion diagnostics adoption.
• United Kingdom: Anticipated to secure USD 1,243.71 million with 7.75% market share and 18.4% CAGR, supported by national genomics research programs.
• China: Market estimated at USD 2,024.12 million with 12.61% share and 18.9% CAGR, owing to policy-backed genetic screening programs.
• Germany: Expected to reach USD 1,135.32 million with 7.07% market share and CAGR of 18.1%, driven by growing biomarker testing usage.
• Japan: Forecasted to record USD 1,121.48 million with 6.99% share and 18.5% CAGR due to growing relevance in personalized oncology.

Imaging: Imaging accounts for 33% of total diagnostic usage. CT scans and MRIs are used in 67% of suspected cancer evaluations. PET-CT is deployed in 26% of tumor staging procedures. Mammography is used in 74% of breast cancer screenings. Cancer Diagnostics Market Share for imaging remains dominant in hospital-based cancer centers.

Imaging diagnostics are forecasted to grow significantly, reaching USD 32,365.81 million by 2034, representing 33.32% market share with a steady CAGR of 17.1% through the forecast period.

Top 5 Major Dominant Countries in the Imaging Segment

• United States: Imaging segment is projected to reach USD 8,496.37 million with 26.26% share and 16.9% CAGR due to advanced radiological infrastructure.
• Germany: Forecasted at USD 3,087.56 million with 9.54% share and 16.8% CAGR, encouraged by widespread radiology system adoption.
• China: Market expected at USD 4,823.92 million with 14.91% share and 17.5% CAGR supported by government-funded imaging upgrades.
• Japan: Estimated at USD 2,836.69 million with 8.77% share and 17.2% CAGR due to increasing cancer-related imaging procedures.
• France: Market to reach USD 2,018.96 million with 6.24% share and 16.6% CAGR driven by integrated diagnostic strategies.

Endoscopy: Endoscopic procedures are applied in 41% of gastrointestinal and colorectal cancer diagnostics. Colonoscopy is used in 64% of colorectal screenings. Bronchoscopy contributes to 36% of lung cancer detection. Technological enhancements have enabled 3D visualization in 47% of facilities.

The Endoscopy segment is projected to attain USD 8,682.93 million by 2034, acquiring 8.94% market share and expanding at a CAGR of 17.6% over the forecast period.

Top 5 Major Dominant Countries in the Endoscopy Segment

• United States: Estimated to achieve USD 2,184.18 million with 25.15% share and 17.3% CAGR due to high GI and bronchial diagnostics.
• China: Expected to reach USD 1,279.36 million with 14.73% share and 17.9% CAGR driven by early cancer detection programs.
• Japan: Market value at USD 1,051.45 million with 12.10% share and 17.8% CAGR due to robust endoscopic innovation.
• Germany: Forecasted to record USD 839.45 million with 9.66% share and 17.2% CAGR with strong pathology support.
• South Korea: Expected at USD 694.31 million with 7.99% share and 17.4% CAGR with national health policy integration.

Biopsy: Biopsy is used in 59% of confirmed cancer diagnoses. Fine needle aspiration accounts for 38% of solid tumor confirmations. Image-guided biopsies are applied in 44% of lung and liver cancer diagnostics. Core needle biopsy is used in 62% of breast cancer confirmations. Biopsy remains critical in tumor classification and grading.

Biopsy diagnostics are anticipated to reach USD 15,577.85 million by 2034, securing 16.04% market share and progressing at a CAGR of 17.3% from 2025 onward.

Top 5 Major Dominant Countries in the Biopsy Segment

• United States: Forecasted to attain USD 4,073.23 million with 26.15% share and 17.2% CAGR as biopsy remains the diagnostic gold standard.
• Germany: Market to reach USD 1,523.67 million with 9.78% share and 16.9% CAGR through integrated hospital and lab diagnostics.
• China: Estimated at USD 2,119.34 million with 13.61% share and 17.8% CAGR due to increasing biopsy-assisted cancer detections.
• Japan: Expected to attain USD 1,218.67 million with 7.82% share and 17.1% CAGR amid robotic biopsy adoption.
• India: Forecasted at USD 991.72 million with 6.36% share and 17.7% CAGR backed by diagnostic imaging convergence.

BY APPLICATION

Breast Cancer: Breast cancer represents 23% of diagnostic applications. Mammography is deployed in 74% of screenings. Biopsies confirm 88% of suspicious lumps. BRCA testing is used in 54% of cases with genetic risk. AI in mammogram analysis is adopted in 41% of hospitals.

The Breast Cancer diagnostics segment is projected to reach USD 28,354.25 million by 2034, accounting for 29.20% market share, growing steadily at a CAGR of 17.3% due to widespread screening programs.

Top 5 Major Dominant Countries in the Breast Cancer Application

• United States: Breast cancer diagnostics will reach USD 7,832.57 million, holding a 27.62% market share and a 17.2% CAGR, driven by mammography and genetic testing advancements.
• Germany: Market expected at USD 2,716.64 million, with 9.58% share and 17.0% CAGR, supported by state-funded breast cancer awareness and imaging campaigns.
• India: Segment forecasted to hit USD 2,006.61 million, commanding a 7.08% share and 17.9% CAGR due to increased detection programs in urban healthcare settings.
• China: Market size projected at USD 3,126.85 million with 11.02% share and 17.6% CAGR, benefiting from expanding diagnostic infrastructure and public health initiatives.
• Japan: Breast cancer diagnostics will reach USD 2,246.13 million, securing a 7.92% share and a 17.4% CAGR as early detection becomes more prevalent in national programs.

Lung Cancer: Lung cancer contributes 18% to the Cancer Diagnostics Market. CT scans are used in 81% of screenings. Liquid biopsies are used in 36% of recurrence monitoring. Biomarker EGFR testing is conducted in 57% of non-small cell lung cancer diagnoses. Endoscopic biopsy tools are applied in 47% of diagnostic settings.

The Lung Cancer diagnostics market is set to grow to USD 20,745.56 million by 2034, capturing a 21.37% market share and achieving a CAGR of 17.5% due to high mortality reduction efforts.

Top 5 Major Dominant Countries in the Lung Cancer Application

• United States: Lung cancer diagnostics will reach USD 5,396.89 million, representing a 26.01% share and 17.2% CAGR due to low-dose CT and AI integration in screenings.
• China: Projected to reach USD 3,101.17 million with a 14.95% market share and 17.9% CAGR, supported by early diagnosis policies for high-risk populations.
• Germany: Market estimated at USD 1,721.14 million, contributing 8.29% share and 17.1% CAGR driven by AI-powered radiology systems in oncology departments.
• Japan: Forecasted to attain USD 1,424.87 million with 6.87% share and 17.3% CAGR supported by rising bronchoscopy-based diagnosis methods.
• South Korea: Market will grow to USD 1,187.38 million, with 5.72% share and 17.4% CAGR due to genetic testing and imaging system modernization.

Colorectal Cancer: Colorectal cancer diagnostics account for 15% of procedures. Colonoscopy is used in 64% of screenings. Fecal immunochemical tests (FIT) are used in 43% of population-wide screening programs. Biopsies confirm diagnosis in 61% of cases. Genetic tests for KRAS and BRAF are used in 38% of colorectal cancer protocols.

Colorectal Cancer diagnostics are projected to reach USD 12,672.43 million by 2034, securing 13.05% market share with a 17.2% CAGR due to growing use of non-invasive screening tools.

Top 5 Major Dominant Countries in the Colorectal Cancer Application

• United States: Market to grow to USD 3,564.38 million, capturing 28.11% market share and 17.1% CAGR, with colonoscopy and FIT becoming standard in routine checks.
• Germany: Forecasted to reach USD 1,263.71 million, representing a 9.96% share and 16.8% CAGR, supported by national colorectal screening programs.
• China: Market size estimated at USD 1,765.84 million, with a 13.93% share and 17.7% CAGR driven by fecal DNA testing and endoscopy availability.
• Japan: Market anticipated to hit USD 1,129.42 million, holding an 8.91% share and 17.2% CAGR due to advanced hospital-based diagnostics.
• India: Market forecasted to reach USD 983.43 million, with 7.76% share and 17.5% CAGR due to awareness drives and growing testing adoption.

Melanoma: Melanoma diagnostics account for 9% of total cancer-related procedures. Dermoscopy is used in 66% of skin examinations. Biopsy confirms diagnosis in 92% of suspected lesions. Genetic testing for BRAF mutations is performed in 41% of advanced melanoma cases.

Melanoma diagnostics are expected to grow to USD 6,403.29 million by 2034, securing a 6.59% market share, with a steady CAGR of 17.3% driven by image-based dermatological tools.

Top 5 Major Dominant Countries in the Melanoma Application

• United States: Market will hit USD 2,066.48 million, contributing 32.27% of share and 17.1% CAGR due to dermoscopy and AI-supported skin lesion analysis.
• Australia: Expected to reach USD 981.12 million, with 15.32% market share and 17.6% CAGR, led by high incidence and widespread screening infrastructure.
• Germany: Forecasted at USD 644.32 million, contributing 10.06% share and 17.0% CAGR driven by national skin cancer early detection campaigns.
• Canada: Market projected at USD 527.67 million, with an 8.24% share and 17.5% CAGR as telemedicine adoption supports rural melanoma screening.
• France: Market size to reach USD 486.91 million, holding a 7.60% share and 16.8% CAGR due to digital dermatology innovations.

Others: Other cancers including pancreatic, liver, and bladder contribute 35% to diagnostic applications. MRI is used in 48% of liver cancer evaluations. Urothelial markers are applied in 31% of bladder cancer diagnoses. Liquid biopsy usage is increasing in pancreatic cancer, now representing 27% of testing strategies.

Other cancers including prostate, liver, and bladder are projected to collectively reach USD 29,930.22 million by 2034, commanding 30.83% share with a strong CAGR of 17.5%.

Top 5 Major Dominant Countries in the Others Application

• United States: Market forecasted to reach USD 8,219.36 million, with 27.47% share and 17.3% CAGR due to technological integration in liver and prostate cancer diagnostics.
• China: Projected to reach USD 4,321.87 million with 14.44% share and 17.8% CAGR led by molecular testing advancements for liver cancer.
• India: Market size expected to be USD 2,674.91 million, accounting for 8.94% share and 18.0% CAGR, supported by growing demand in diagnostic hospitals.
• Germany: Market will grow to USD 2,618.57 million, capturing 8.75% share and 16.9% CAGR from integrated pathology platforms.
• Japan: Expected to reach USD 2,365.78 million with 7.91% share and 17.4% CAGR owing to robust expansion of multi-cancer diagnostic centers.

Cancer Diagnostics Market Regional Outlook

The Cancer Diagnostics Market Outlook reflects rising global demand, with 64% of healthcare systems expanding screening programs and 53% integrating AI technologies. Genetic testing, imaging, and laboratory diagnostics are rapidly advancing, while North America leads with 33% share.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America maintains its leadership in the Cancer Diagnostics Market, holding 33% of global share. The region has over 5,200 dedicated oncology facilities and performs 61% of its cancer diagnoses through AI-integrated imaging and laboratory tools. Genetic testing services are accessible in 72% of healthcare systems.

North America is projected to reach a market size of USD 31,874.88 million by 2034, commanding a 32.83% global share and growing at a stable CAGR of 17.2% due to strong healthcare infrastructure.

North America - Major Dominant Countries in the Cancer Diagnostics Market

• United States: The market is expected to reach USD 26,330.47 million with 82.58% regional share and 17.2% CAGR due to dominance in imaging, genomics, and AI-integrated cancer diagnostics.
• Canada: Estimated to grow to USD 3,128.38 million with a 9.81% share and 17.4% CAGR as cancer screening programs expand across provinces and private-sector labs scale.
• Mexico: Forecasted to attain USD 1,032.23 million with a 3.23% share and 17.8% CAGR driven by growing diagnostic investments in public and private hospitals.
• Cuba: Market size will reach USD 593.45 million, representing 1.86% share and 16.9% CAGR due to increasing accessibility to government-sponsored diagnostic solutions.
• Dominican Republic: Anticipated to grow to USD 530.35 million with a 1.66% share and 17.5% CAGR supported by regional partnerships and rising cancer awareness initiatives.

EUROPE

Europe represents 28% of global Cancer Diagnostics Market Share. More than 2,100 screening centers operate across Germany, France, and the UK. Breast and colorectal cancer screenings are provided to 64% of citizens above age 40. Digital pathology adoption stands at 41% across national health services.

Europe’s Cancer Diagnostics Market is projected to reach USD 24,095.29 million by 2034, holding 24.81% market share and achieving a 17.0% CAGR through policy-driven diagnostic advancements and early detection strategies.

Europe - Major Dominant Countries in the Cancer Diagnostics Market

• Germany: Expected to reach USD 7,568.74 million with a 31.40% regional share and 17.0% CAGR due to strong government-backed diagnostic networks and biomarker-based screening tools.
• France: Market forecasted at USD 4,346.24 million with 18.03% share and 16.8% CAGR, driven by universal screening protocols and AI radiology adoption.
• United Kingdom: Estimated to achieve USD 3,918.19 million, securing 16.26% market share and 17.1% CAGR through NHS-facilitated genomic cancer testing programs.
• Italy: Market projected to reach USD 3,127.21 million, holding 12.97% share and 16.9% CAGR, with consistent uptake in hospital-based endoscopy and biopsy services.
• Spain: Expected to grow to USD 2,542.91 million with a 10.55% share and 17.2% CAGR owing to increased demand for colorectal and breast cancer diagnostics.

ASIA-PACIFIC

Asia-Pacific holds 24% of market share, driven by large population pools and increasing investment in cancer infrastructure. Japan and China account for 62% of regional demand. In India, cancer diagnostics have expanded by 49% in urban centers. Endoscopy and imaging are dominant diagnostic methods in the region.

Asia-Pacific is projected to expand significantly, reaching USD 21,092.47 million by 2034 with 21.72% global share and 17.7% CAGR, fueled by population growth and diagnostic infrastructure development.

Asia-Pacific - Major Dominant Countries in the Cancer Diagnostics Market

• China: China will dominate the region with USD 8,725.32 million market size, 41.37% share and 17.8% CAGR due to nationwide cancer prevention and screening initiatives.
• Japan: Market is expected to reach USD 5,302.87 million with 25.13% share and 17.5% CAGR as hospitals integrate imaging and genetic diagnostics in cancer pathways.
• India: Market projected at USD 3,148.26 million, holding 14.92% share and 17.9% CAGR, fueled by growth in urban diagnostics and public-private health partnerships.
• South Korea: Expected to achieve USD 2,049.33 million with 9.71% market share and 17.6% CAGR owing to adoption of AI imaging and biomarker testing tools.
• Australia: Market size forecasted at USD 1,866.69 million with 8.85% share and 17.3% CAGR driven by strong melanoma screening programs and tele-oncology tools.

MIDDLE EAST & AFRICA

Middle East & Africa capture 9% of the market. UAE and Saudi Arabia account for 61% of regional testing facilities. Access to advanced diagnostics remains limited in Sub-Saharan Africa, where only 29% of hospitals have imaging-based cancer detection systems. Laboratory testing dominates in public sector hospitals.

The Middle East and Africa region is expected to grow to USD 7,043.34 million by 2034, comprising 7.25% of global share and expanding at a CAGR of 17.5% with rising healthcare modernization.

Middle East and Africa - Major Dominant Countries in the Cancer Diagnostics Market

• UAE: Market size projected to hit USD 1,762.45 million with 25.02% share and 17.6% CAGR as diagnostic imaging and laboratory testing services continue expanding rapidly.
• Saudi Arabia: Forecasted at USD 1,485.26 million with a 21.08% share and 17.5% CAGR due to large-scale hospital projects and early detection initiatives.
• South Africa: Expected to reach USD 1,291.12 million, holding 18.33% share and 17.3% CAGR led by improvements in biopsy and lab infrastructure.
• Nigeria: Market projected at USD 1,068.24 million, capturing 15.16% share and 17.8% CAGR driven by regional diagnostic funding and awareness programs.
• Egypt: Anticipated to grow to USD 983.98 million with 13.96% share and 17.4% CAGR as more hospitals adopt advanced cancer testing modalities.

List of Top Cancer Diagnostics Companies

• Roche Diagnostics
• Siemens Healthcare
• Thermo Fisher Scientific, Inc.
• QIAGEN N.V.
• Philips Healthcare
• Agilent Technologies, Inc.
• Abbott Laboratories, Inc.
• Becton, Dickinson and Company
• R. Bard, Inc.
• GE Healthcare
• Illumina, Inc.
• Dickinson and Company

Top Two Companies by Market Share:

• Roche Diagnostics holds 19% of global Cancer Diagnostics Market Share with strong imaging and laboratory testing portfolios.
• Thermo Fisher Scientific accounts for 17% of molecular and genetic testing solutions used worldwide.

Investment Analysis and Opportunities

Cancer Diagnostics Market Growth is supported by rising investment in genomic and AI-based diagnostics. From 2023 to 2025, global funding for cancer diagnostics R&D exceeded USD 8.4 billion in combined public-private grants. Venture capital investments in AI diagnostic platforms grew by 62% during this period. Hospitals and health networks in Europe and Asia are allocating 41% more capital expenditure toward upgrading diagnostic equipment.

Public screening programs received a 33% increase in budget allocation globally. Over 47 new cancer diagnostic startups have emerged since 2023, focusing on liquid biopsy, biomarker identification, and portable imaging systems. The Cancer Diagnostics Industry Report highlights increasing cross-border collaborations and technology licensing agreements driving innovation.

New Product Development

Between 2023 and 2025, more than 57 novel diagnostic products have entered the market. Thermo Fisher introduced a new NGS-based lung cancer panel used in 28% of tertiary hospitals. Roche launched a multiplex IHC kit used in 31% of breast cancer diagnostics. GE Healthcare unveiled an AI-assisted PET scanner adopted in 36% of urban hospitals.

Philips released a real-time MRI tool integrated with cancer grading software, used in 22% of new installations. Illumina expanded its genomic testing panel from 100 to 150 cancer-related genes. Cancer Diagnostics Market Outlook reveals that product innovation remains crucial for clinical differentiation and healthcare partnerships.

Five Recent Developments

• Roche launched VENTANA MMR IHC Panel in 2024, now used in 38% of colorectal cancer assessments globally.
• Siemens Healthineers introduced syngo.via VB40 AI suite in 2023, adopted by 42% of radiology departments.
• Thermo Fisher released Oncomine Dx Target Test updates, used in 44% of NSCLC genomic diagnostics by 2025.
• QIAGEN launched QIAcuity digital PCR platform in 2025, enhancing biomarker sensitivity by 61%.
• Illumina expanded oncology panels in 2024 to support 47% more gene targets in breast and ovarian cancer detection.

Report Coverage of Cancer Diagnostics Market

This Cancer Diagnostics Market Research Report covers in-depth analysis of market segmentation by type and application, regional dynamics, competitive landscape, and recent technological innovations. The report includes over 187 data points and fact-based insights spanning 2019 to 2025. Cancer Diagnostics Market Size is segmented into laboratory tests, genetic testing, imaging, biopsy, and endoscopy with application breakdown across key cancer types.

The report evaluates over 50 regional markets, covering diagnostics access, infrastructure growth, and screening policies. Cancer Diagnostics Industry Report includes profiles of 12 major players with insights into their market share, product launches, and strategic investments. It offers data-driven intelligence tailored to B2B buyers, stakeholders, hospital procurement teams, and diagnostics OEMs.

Cancer Diagnostics Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 26913.05 Million in 2026
Market Size Value By	USD 114002.16 Million by 2035
Growth Rate	CAGR of 17.4% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Laboratory Tests Genetic Tests Imaging Endoscopy Biopsy By Application : Breast Cancer Lung Cancer Colorectal Cancer Melanoma Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample